Table of Contents Chapter 1 Overview of Bioengineered Protein Drugs 1.1 Definition of Bioengineered Protein Drugs in This Report 1.2 Commercial Types of Bioengineered Protein Drugs 1.2.1 Therapeutic Proteins 1.2.2 Monoclonal Antibodies 1.2.3 Vaccines 1.3 Downstream Application of Bioengineered Protein Drugs 1.3.1 Diabetes and Hormonal Disorders 1.3.2 Genetic and Fertility Disorders 1.3.3 Cancers 1.3.4 Organ Transplants 1.3.5 Others 1.4 Development History of Bioengineered Protein Drugs 1.5 Market Status and Trend of Bioengineered Protein Drugs 2013-2023 1.5.1 North America Bioengineered Protein Drugs Market Status and Trend 2013-2023 1.5.2 Regional Bioengineered Protein Drugs Market Status and Trend 2013-2023 Chapter 2 North America Market Status and Forecast by Regions 2.1 Market Status of Bioengineered Protein Drugs in North America 2013-2017 2.2 Consumption Market of Bioengineered Protein Drugs in North America by Regions 2.2.1 Consumption Volume of Bioengineered Protein Drugs in North America by Regions 2.2.2 Revenue of Bioengineered Protein Drugs in North America by Regions 2.3 Market Analysis of Bioengineered Protein Drugs in North America by Regions 2.3.1 Market Analysis of Bioengineered Protein Drugs in United States 2013-2017 2.3.2 Market Analysis of Bioengineered Protein Drugs in Canada 2013-2017 2.3.3 Market Analysis of Bioengineered Protein Drugs in Mexico 2013-2017 2.4 Market Development Forecast of Bioengineered Protein Drugs in North America 2018-2023 2.4.1 Market Development Forecast of Bioengineered Protein Drugs in North America 2018-2023 2.4.2 Market Development Forecast of Bioengineered Protein Drugs by Regions 2018-2023 Chapter 3 North America Market Status and Forecast by Types 3.1 Whole North America Market Status by Types 3.1.1 Consumption Volume of Bioengineered Protein Drugs in North America by Types 3.1.2 Revenue of Bioengineered Protein Drugs in North America by Types 3.2 North America Market Status by Types in Major Countries 3.2.1 Market Status by Types in United States 3.2.2 Market Status by Types in Canada 3.2.3 Market Status by Types in Mexico 3.3 Market Forecast of Bioengineered Protein Drugs in North America by Types Chapter 4 North America Market Status and Forecast by Downstream Industry 4.1 Demand Volume of Bioengineered Protein Drugs in North America by Downstream Industry 4.2 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Major Countries 4.2.1 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in United States 4.2.2 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Canada 4.2.3 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Mexico 4.3 Market Forecast of Bioengineered Protein Drugs in North America by Downstream Industry Chapter 5 Market Driving Factor Analysis of Bioengineered Protein Drugs 5.1 North America Economy Situation and Trend Overview 5.2 Bioengineered Protein Drugs Downstream Industry Situation and Trend Overview Chapter 6 Bioengineered Protein Drugs Market Competition Status by Major Players in North America 6.1 Sales Volume of Bioengineered Protein Drugs in North America by Major Players 6.2 Revenue of Bioengineered Protein Drugs in North America by Major Players 6.3 Basic Information of Bioengineered Protein Drugs by Major Players 6.3.1 Headquarters Location and Established Time of Bioengineered Protein Drugs Major Players 6.3.2 Employees and Revenue Level of Bioengineered Protein Drugs Major Players 6.4 Market Competition News and Trend 6.4.1 Merger, Consolidation or Acquisition News 6.4.2 Investment or Disinvestment News 6.4.3 New Product Development and Launch Chapter 7 Bioengineered Protein Drugs Major Manufacturers Introduction and Market Data 7.1 Abbott Laboratories 7.1.1 Company profile 7.1.2 Representative Bioengineered Protein Drugs Product 7.1.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories 7.2 F. Hoffmann-La Roche Ltd 7.2.1 Company profile 7.2.2 Representative Bioengineered Protein Drugs Product 7.2.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd 7.3 Amgen, Inc. 7.3.1 Company profile 7.3.2 Representative Bioengineered Protein Drugs Product 7.3.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Amgen, Inc. 7.4 Bayer AG 7.4.1 Company profile 7.4.2 Representative Bioengineered Protein Drugs Product 7.4.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Bayer AG 7.5 Merck & Co., Inc. 7.5.1 Company profile 7.5.2 Representative Bioengineered Protein Drugs Product 7.5.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Merck & Co., Inc. 7.6 Dr. Reddy's Laboratories Ltd. 7.6.1 Company profile 7.6.2 Representative Bioengineered Protein Drugs Product 7.6.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Dr. Reddy's Laboratories Ltd. 7.7 Biocon Ltd. 7.7.1 Company profile 7.7.2 Representative Bioengineered Protein Drugs Product 7.7.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Biocon Ltd. 7.8 Eli Lilly and Company 7.8.1 Company profile 7.8.2 Representative Bioengineered Protein Drugs Product 7.8.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly and Company 7.9 Sanofi 7.9.1 Company profile 7.9.2 Representative Bioengineered Protein Drugs Product 7.9.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Sanofi 7.10 GlaxoSmithKline plc 7.10.1 Company profile 7.10.2 Representative Bioengineered Protein Drugs Product 7.10.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc 7.11 Johnson & Johnson 7.11.1 Company profile 7.11.2 Representative Bioengineered Protein Drugs Product 7.11.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson 7.12 JanssenNovartis AG 7.12.1 Company profile 7.12.2 Representative Bioengineered Protein Drugs Product 7.12.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of JanssenNovartis AG 7.13 Panacea Biotec 7.13.1 Company profile 7.13.2 Representative Bioengineered Protein Drugs Product 7.13.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Panacea Biotec 7.14 ProBioGen AG 7.14.1 Company profile 7.14.2 Representative Bioengineered Protein Drugs Product 7.14.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of ProBioGen AG Chapter 8 Upstream and Downstream Market Analysis of Bioengineered Protein Drugs 8.1 Industry Chain of Bioengineered Protein Drugs 8.2 Upstream Market and Representative Companies Analysis 8.3 Downstream Market and Representative Companies Analysis Chapter 9 Cost and Gross Margin Analysis of Bioengineered Protein Drugs 9.1 Cost Structure Analysis of Bioengineered Protein Drugs 9.2 Raw Materials Cost Analysis of Bioengineered Protein Drugs 9.3 Labor Cost Analysis of Bioengineered Protein Drugs 9.4 Manufacturing Expenses Analysis of Bioengineered Protein Drugs Chapter 10 Marketing Status Analysis of Bioengineered Protein Drugs 10.1 Marketing Channel 10.1.1 Direct Marketing 10.1.2 Indirect Marketing 10.1.3 Marketing Channel Development Trend 10.2 Market Positioning 10.2.1 Pricing Strategy 10.2.2 Brand Strategy 10.2.3 Target Client 10.3 Distributors/Traders List Chapter 11 Report Conclusion Chapter 12 Research Methodology and Reference 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Reference

List of Tables Table Advantage and Disadvantage of Therapeutic Proteins Table Advantage and Disadvantage of Monoclonal Antibodies Table Advantage and Disadvantage of Vaccines Table Consumption Volume of Bioengineered Protein Drugs in North America by Regions 2013-2017 Table Revenue of Bioengineered Protein Drugs in North America by Regions 2013-2017 Table Consumption Volume of Bioengineered Protein Drugs in North America by Regions 2018-2023 Table Revenue of Bioengineered Protein Drugs in North America by Regions 2018-2023 Table Consumption Volume of Bioengineered Protein Drugs in North America by Types 2013-2017 Table Revenue of Bioengineered Protein Drugs in North America by Types 2013-2017 Table Consumption Volume of Bioengineered Protein Drugs by Types in United States 2013-2017 Table Consumption Volume of Bioengineered Protein Drugs by Types in Canada 2013-2017 Table Consumption Volume of Bioengineered Protein Drugs by Types in Mexico 2013-2017 Table Consumption Volume Forecast of Bioengineered Protein Drugs in North America by Types 2018-2023 Table Revenue Forecast of Bioengineered Protein Drugs in North America by Types 2018-2023 Table Demand Volume of Bioengineered Protein Drugs in North America by Downstream Industry 2013-2017 Table Demand Volume of Bioengineered Protein Drugs by Downstream Industry in United States 2013-2017 Table Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Canada 2013-2017 Table Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Mexico 2013-2017 Table Demand Volume Forecast of Bioengineered Protein Drugs in North America by Downstream Industry 2018-2023 Table Sales Volume of Bioengineered Protein Drugs in North America by Major Players 2013-2017 Table Revenue of Bioengineered Protein Drugs in North America by Major Players 2013-2017 Table Headquarters Location and Established Time of Bioengineered Protein Drugs Major Players Table Employees and Revenue Level of Bioengineered Protein Drugs Major Players Table Representative Bioengineered Protein Drugs Product One of Abbott Laboratories Table Representative Bioengineered Protein Drugs Product Two of Abbott Laboratories Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories 2013-2017 Table Representative Bioengineered Protein Drugs Product One of F. Hoffmann-La Roche Ltd Table Representative Bioengineered Protein Drugs Product Two of F. Hoffmann-La Roche Ltd Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd 2013-2017 Table Representative Bioengineered Protein Drugs Product One of Amgen, Inc. Table Representative Bioengineered Protein Drugs Product Two of Amgen, Inc. Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Amgen, Inc. 2013-2017 Table Representative Bioengineered Protein Drugs Product One of Bayer AG Table Representative Bioengineered Protein Drugs Product Two of Bayer AG Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Bayer AG 2013-2017 Table Representative Bioengineered Protein Drugs Product One of Merck & Co., Inc. Table Representative Bioengineered Protein Drugs Product Two of Merck & Co., Inc. Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Merck & Co., Inc. 2013-2017 Table Representative Bioengineered Protein Drugs Product One of Dr. Reddy's Laboratories Ltd. Table Representative Bioengineered Protein Drugs Product Two of Dr. Reddy's Laboratories Ltd. Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Dr. Reddy's Laboratories Ltd. 2013-2017 Table Representative Bioengineered Protein Drugs Product One of Biocon Ltd. Table Representative Bioengineered Protein Drugs Product Two of Biocon Ltd. Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Biocon Ltd. 2013-2017 Table Representative Bioengineered Protein Drugs Product One of Eli Lilly and Company Table Representative Bioengineered Protein Drugs Product Two of Eli Lilly and Company Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly and Company 2013-2017 Table Representative Bioengineered Protein Drugs Product One of Sanofi Table Representative Bioengineered Protein Drugs Product Two of Sanofi Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Sanofi 2013-2017 Table Representative Bioengineered Protein Drugs Product One of GlaxoSmithKline plc Table Representative Bioengineered Protein Drugs Product Two of GlaxoSmithKline plc Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc 2013-2017 Table Representative Bioengineered Protein Drugs Product One of Johnson & Johnson Table Representative Bioengineered Protein Drugs Product Two of Johnson & Johnson Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson 2013-2017 Table Representative Bioengineered Protein Drugs Product One of JanssenNovartis AG Table Representative Bioengineered Protein Drugs Product Two of JanssenNovartis AG Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of JanssenNovartis AG 2013-2017 Table Representative Bioengineered Protein Drugs Product One of Panacea Biotec Table Representative Bioengineered Protein Drugs Product Two of Panacea Biotec Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Panacea Biotec 2013-2017 Table Representative Bioengineered Protein Drugs Product One of ProBioGen AG Table Representative Bioengineered Protein Drugs Product Two of ProBioGen AG Table Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of ProBioGen AG 2013-2017